

**CLINICAL REVIEW****Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck**

**Sandra Nuyts MD, PhD<sup>1,2</sup>** | **Heleen Bollen MD<sup>1,2</sup>** | **Avraham Eisbruch MD<sup>3</sup>** | **June Corry MD<sup>4</sup>** | **Primož Strojjan MD, PhD<sup>5</sup>** | **Antti A. Mäkitie MD, PhD<sup>6</sup>** | **Johannes A. Langendijk MD, PhD<sup>7</sup>** | **William M. Mendenhall MD<sup>8</sup>** | **Robert Smee FRANZCR, MBBS<sup>9</sup>** | **Remco DeBree MD, PhD<sup>10</sup>** | **Anne W. M. Lee MD<sup>11</sup>** | **Alessandra Rinaldo MD, FRCSEd ad hominem, FRCS (Eng, Ir) ad eundem, FRCSGlasg, FACS<sup>12</sup>** | **Alfio Ferlito MD, FRCSEd ad hominem, FRCS (Eng, Glasg, Ir) ad eundem, FDSRCS ad eundem, FACS, FHKCORL, FRCPath, FASCP, IFCAP<sup>13</sup>**

<sup>1</sup>Laboratory of Experimental Radiotherapy, Department of Oncology, Leuven, Belgium

<sup>2</sup>Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

<sup>3</sup>Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA

<sup>4</sup>Division of Medicine, Department of Radiation Oncology, St. Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia

<sup>5</sup>Department of Radiation Oncology, Institute of Oncology, University of Ljubljana, Ljubljana, Slovenia

<sup>6</sup>Department of Otorhinolaryngology – Head and Neck Surgery, HUS Helsinki University Hospital, University of Helsinki, Helsinki, Finland

<sup>7</sup>Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands

<sup>8</sup>Department of Radiation Oncology, College of Medicine, University of Florida, Gainesville, Florida, USA

<sup>9</sup>Department of Radiation Oncology, The Prince of Wales Cancer Centre, Sydney, New South Wales, Australia

<sup>10</sup>Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Centre, University Medical Centre Utrecht, Utrecht, the Netherlands

<sup>11</sup>Department of Clinical Oncology, University of Hong Kong, Hong Kong, China

<sup>12</sup>Department of Otolaryngology, University of Udine School of Medicine, Udine, Italy

<sup>13</sup>International Head and Neck Scientific Group, Udine, Italy

**Correspondence**

Sandra Nuyts, Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium.  
Email: sandra.nuyts@uzleuven.be

**Abstract**

Cancers of the head and neck region often present with nodal involvement. There is a long-standing convention within the community of head and neck radiation oncology to irradiate both sides of the neck electively in almost all cases to include both macroscopic and microscopic disease extension (so called elective nodal volume). International guidelines for the selection and delineation of the elective lymph nodes were published in the early 2000s and were updated recently. However, diagnostic imaging techniques have improved the accuracy and reliability of nodal staging and as a result,

Sandra Nuyts and Heleen Bollen are shared first authors.

This paper was written by members and invitees of the International Head and Neck Scientific Group ([www.IHNSG.com](http://www.IHNSG.com)).

small metastases that used to remain undetected and were thus in the past included in the elective nodal volume, will now be included in high-dose volumes. Furthermore, the elective nodal areas are situated close to the parotid glands, the submandibular glands and the swallowing muscles. Therefore, irradiation of a smaller, more selected volume of the elective nodes could reduce treatment-related toxicity. Several researchers consider the current bilateral elective neck irradiation strategies an overtreatment and show growing interest in a unilateral nodal irradiation in selected patients. The aim of this article is to give an overview of the current evidence about the indications and benefits of unilateral nodal irradiation and the use of SPECT/CT-guided nodal irradiation in squamous cell carcinomas of the head and neck.

#### KEYWORDS

head and neck cancer, nodal volume selection, radiotherapy, toxicity reduction, volume de-escalation

## 1 | INTRODUCTION

Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer and cause of cancer-related death worldwide with more than 500 000 new cases and 380 000 deaths yearly.<sup>1</sup> HNSCC is usually diagnosed in a locally advanced but curable stage and can be treated with either surgery or radiotherapy, with or without concomitant radiosensitizing chemotherapy. The well-considered use of these treatment modalities has led to a current 5-year overall survival rate for patients with HNSCC of 50%–90%, in function of the initial tumor stage.<sup>2–4</sup> The head and neck area has a rich regional lymphatic network and therefore HNSCC has a strong tendency to metastasize to the regional lymph nodes. As the presence of regional metastases is an important prognostic factor in HNSCC,<sup>5</sup> determining lymph node metastases is critical for both prognosis and treatment choice. It is not uncommon that small nodal metastases remain undetected as they are below the detection threshold of physical examination and diagnostic imaging. Clinically undetectable metastases are also known as “microscopic” or “occult” disease. The patterns of lymphatic drainage in the head and neck area have been assessed by several large-scale studies evaluating the site of nodal metastases in neck dissection specimens.<sup>6–9</sup> Since then, a binary concept was introduced in the radiation treatment of HNSCC, distinguishing separate target volumes for macroscopic disease and for occult disease. The gross tumor volume (GTV) identifies the extent and location of demonstrable macroscopic disease and will encompass the tumor and the detectable lymph node metastases using information

from clinical examination and diagnostic imaging. The clinical target volume (CTV) is created by expansion of the GTV in order to cover potential occult disease spread in the surrounding normal tissue. The target volume for occult lymph node metastases is the elective CTV and will cover the most relevant routes of potential lymphatic spread of disease. Elective nodal irradiation (ENI) has the potential to achieve high control rates in cervical lymph node levels with high risk of subclinical disease.<sup>10,11</sup>

There is a long-standing convention within the head and neck radiation oncology community to irradiate both sides of the neck electively in almost all HNSCCs. International guidelines for the selection and delineation of the elective lymph nodes were published in the early 2000s and were updated recently.<sup>12,13</sup> However, some authors suggest that the current treatment paradigm needs to be reconsidered, as it does not take into account new diagnostic imaging techniques.<sup>14</sup> Recent diagnostic imaging techniques have indeed significantly improved the accuracy and reliability of nodal staging.<sup>15–18</sup> As a result, small metastases that used to remain undetected and were thus included in the elective CTV, will now be included in high-dose volumes and the current elective CTV is likely to have a lower tumor load.<sup>14</sup> Furthermore, the elective nodal areas are situated close to the parotid glands, the submandibular glands and the swallowing muscles. Therefore, irradiation of a smaller, more selected volume of the elective CTV could reduce treatment-related toxicity. Several researchers consider the current bilateral elective neck irradiation (B-ENI) an overtreatment and show growing interest in unilateral nodal irradiation (UNI) in selected patients.

The aim of this article is to give an overview of the current evidence about the indications and benefits of unilateral nodal irradiation (UNI) and SPECT/CT-guided ENI in the definitive radiation treatment of squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx, and larynx.

## 2 | RISK ASSESSMENT FOR OCCULT METASTASES IN CONTRALATERAL cN0 NECK

In HNSCC primarily treated with radiotherapy, the main concern when considering UNI is the potential risk of missing contralateral metastatic lymph nodes. According to the current guidelines, predefined nodal levels should be included in the elective volume if the chance of occult disease exceeds 10%–15%.<sup>13,19–21</sup> The decision whether to treat the contralateral neck electively is based on the probability of micrometastasis for the given subsite. However, HNSCC originates from multiple anatomic regions with differences in potential metastatic spread and we currently have no noninvasive diagnostic modality for identification of occult metastasis in patients with a clinically and radiographically negative neck (cN0). As shown in Table 1, several pathologic studies have investigated the predictors of contralateral metastases for oral cavity cancer (OCSCC),<sup>6,22–28</sup> oropharyngeal cancer (OPSCC),<sup>6,19,29–45</sup> hypopharyngeal cancer (HPC),<sup>19,22,46–53</sup> and laryngeal cancer (LC)<sup>52,54–60</sup> by performing a bilateral neck dissection. International guidelines are based on the results of these studies.<sup>13</sup> However, caution is required, as it concerns heterogeneous and historical data with low patient numbers and short follow-up time. Furthermore, some studies date back from a time that nodal staging was still performed by clinical palpation and the incidence of occult contralateral lymph node metastases (CLNM) will likely be overestimated. However, the studies mentioned in Table 1 stress the complexity of understanding and assessing the patient's individual risk for CLNM.

## 3 | RADIOTHERAPY STUDIES OMITTING CONTRALATERAL NECK IRRADIATION

Several studies have investigated the safety of UNI in OPSCC.<sup>33,61–77</sup> Table 2 provides an overview of all articles in which definitive radiation treatment was limited to the ipsilateral neck and the incidence of contralateral regional failure (cRF) and disease stage were clearly reported. Isolated cRF is generally very low with <2% in all 1206 patients. O'Sullivan et al. were the first to report

TABLE 1 Predictors of occult contralateral metastases based on pathological examination after bilateral neck dissection

OCSCC	OPSCC
T-stage <sup>26–28</sup>	T-stage <sup>29,39,43–45</sup>
Ipsilateral N+ <sup>26,28</sup>	N-stage <sup>30,31,33,42,45</sup>
High histopathological grade <sup>28</sup>	ECE <sup>32,33</sup>
Midline extension <sup>26,27</sup>	Tumor site:
FOM involvement <sup>8,22–25,27</sup>	risk ↑ for BOT, soft palate and posterior pharyngeal wall <sup>19,22,39,41,42</sup>
Tumor site:	risk ↓ for tonsillar carcinoma <sup>34–37,39,42,45</sup>
risk ↑ for FOM and OT <sup>22–25</sup>	
risk ↓ for lateralized OCSCC <sup>6,22</sup>	
HPC	LC
Ipsilateral N+ <sup>46,52,53</sup>	T-stage <sup>59</sup>
Midline extension <sup>46,48–51</sup>	Ipsilateral N+ <sup>56</sup>
Involvement medial wall of PS <sup>50</sup>	Subglottic extension <sup>57</sup>
	ECE <sup>56,57,60</sup>
	Tumor site:
	risk ↑ for supraglottic cancer <sup>52,56–59</sup>
	risk ↓ for glottic cancer (especially T1) <sup>54,55</sup>

Note: General probability of CLNM in lateralized OCSCC is typically <10%; however, higher incidences are reported for FOM and OT tumors. Midline structures in OPSCC show increased risk for CLNM, as opposed to tonsillar cancers. HPC have a high overall incidence for CLNM of ±30%. For T1 glottic tumors, the risk of CLNM is very low. Supraglottic carcinomas are associated with a higher rate of CLNM.

Abbreviations: BOT, base of tongue; ECE, extracapsular extension; FOM, floor-of-mouth; HPC, hypopharyngeal carcinoma; LC, laryngeal carcinoma; OCSCC, oral cavity squamous cell carcinoma; OPSCC, oropharyngeal squamous cell carcinoma; OT, oral tongue; PS, pyriform sinus.

a higher cRF rate in patients with soft palate involvement.<sup>61</sup> Based on their results, most later studies excluded patients with midline involvement. One of the largest series (185 patients) reporting UNI for OPSCC was published by Al-Mamgani et al.<sup>71</sup> Seventy percent of patients had tonsillar cancer, whereas 25% had cancer of the soft palate (≥1 cm from the midline) and 5% of the lateral pharyngeal wall. With a median follow-up of 4.1 years, 1.1% of patients developed cRF. Several smaller retrospective series confirm the reported low rates of cRF in selected patients with OPSCC with a primary tumor ≥1 cm away from the midline.<sup>72–75</sup> However, it is important to note that most studies exclusively included patients with tonsillar cancer. In the few studies that included other OPSCC subsites, tonsillar carcinomas were over-represented.<sup>62,76,77</sup> It is, therefore, generally accepted that patients with lateralized tonsillar OPSCC have a very low risk of cRF. Controversy exists about the risk for patients with cN2 disease, especially cN2b (metastasis in multiple ipsilateral lymph nodes ≤6 cm).<sup>36</sup> High cRF rates were published by Maskell et al. in 2019,

TABLE 2 Overview of 15 studies in which UNI was administered and the incidence of cRF and disease stage were reported

	Sample size	Inclusion criteria	cRF (N)	Isolated cRF (N)	Median FU in months
O'Sullivan et al. <sup>61</sup>	228	cT1-4N0-3 tonsillar cancer	8	3	68
Jackson et al. <sup>70</sup>	136	cT1-4N0-3 tonsillar cancer	4	4	60
Al-Mamgani et al. <sup>71</sup>	185	cT1-3N0-2b well-lateralized OPSCC	2	2	185
Lynch et al. <sup>33</sup>	136	cT1-3N0-3 lateralized tonsillar cancer	8	6	136
Chronowski et al. <sup>69</sup>	102	cT1-2N0-2b lateralized tonsillar cancer	2	1	102
Kennedy et al. <sup>72</sup>	76	cT1-2N0-2b lateralized tonsillar cancer	1	1	76
Dan et al. <sup>75</sup>	61	cT1-3N1-2b lateralized tonsillar cancer	1	1	37
Liu et al. <sup>73</sup>	58	cT1-3N0-3 tonsillar cancer	0	0	102
Jensen et al. <sup>77</sup>	40	cT1-3N0-3 OPSCC	1	1	40
Kagei et al. <sup>68</sup>	32	cT1-4N0-3 lateralized tonsillar and soft palate cancer	0	0	32
Koo et al. <sup>74</sup>	20	cT1-3N0-2b lateralized tonsillar cancer	0	0	20
Cerezo et al. <sup>76</sup>	20	cT1-2N0-2b lateralized OPSCC and OCSCC	0	0	58
Maskell et al. <sup>63</sup>	53	cT1-2N0-2b lateralized tonsillar cancer	NR	4	68
Hu et al. <sup>62</sup>	36	cT1-3N0-2b lateralized OPSCC	0	0	32
Cramer et al. <sup>67</sup>	23	cT1-2N1-2b lateralized tonsillar cancer	0	0	30

Note: Isolated cRF is <2% (23/1206 patients).

Abbreviations: cRF (N), number of patients with contralateral regional failure; isolated cRF (N), number of patients with contralateral regional failure with controlled disease at the primary tumor site; NR, not reported; median FU, follow-up in months.

who reported all cRF to occur in T1 tonsillar primaries with multiple nodes  $\leq 6$  cm.<sup>63</sup> This finding was confirmed by a study of Lynch et al., a series of 136 patients, in which of the six patients that developed true isolated cRF, all had N2b disease.<sup>33</sup> These findings were, however, not confirmed by several other studies that included a significant amount of patients with N2b disease.<sup>62,64–66</sup> The study of Hu et al. reported no cRF, although 62% of patients had multiple involved ipsilateral nodes  $\leq 6$  cm.<sup>62</sup> Cramer et al. reported no cRF in 23 patients treated with UNI for lateralized T1-2N1-2b tonsillar cancer, of which 18/23 patients were N2b.<sup>67</sup> In a propensity-score matched analysis of 241 patients with tonsillar cancer who underwent tonsillectomy and were treated with UNI, Kim et al. found no cRF in 61 patients with pathologic T1-2N2a.<sup>78</sup> Among 79 patients with N2b disease, cRF was 7.9% (3/38) in ipsilateral RT group versus 0% in bilateral RT group. However, two of the three patients with cRF also experienced local recurrence.

It is clear that the administration of UNI has been extensively investigated in tonsillar cancer and, to lesser extent, in other OPSCC subsites. However, less research is carried out in OCSCC, HPC, and LC. Cerezo et al. were the only authors that, in addition to patients with OPSCC, also included patients with primary OCSCC.<sup>76</sup> The study included eight patients with cT1-T2 lateralized tonsillar carcinoma and 12 patients with cT1-T2 lateralized primary tumor of the oral cavity. With a

median follow-up time of 3 years, no cRF was found. Just recently, an abstract was published, examining dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer. For OPSCC, only involved and immediately adjacent stations were treated. At a median follow-up of 24.7 months for surviving patients, there were no solitary elective nodal recurrences.<sup>79</sup> Because of the higher incidence of contralateral metastasis in HPC and LC, there are no data available on the incidence of cRF in patients treated with UNI in this patient population. In the above-mentioned abstract, at least bilateral levels II and III were treated in all LC patients.

Based on the previously mentioned studies, we can conclude that there is a slowly growing evidence in literature supporting the concept of unilateral nodal irradiation (UNI) in well-lateralized OPSCC with very limited risk of cRF. However, caution is required translating the results to daily practice. First of all, almost all studies are single-center retrospective analyses, with small sample sizes and rather short follow-up time. Second, cRF varied widely between all reported studies. One reason for this may be that the inclusion criteria for UNI among centers differed. Higher incidence of cRF might partly be explained by the fact that in some centers patients with N3 or T3 were treated unilaterally, while some centers only included patients with T1-2. Nevertheless, in most studies, T3 tumors were under-represented in the group

that was treated with UNI, as they are more likely to involve midline structures. Therefore, conclusions can only be safely drawn for T1-T2 tumors. Understandably, distinctly higher cRF rates were found in the few studies that included patients with tumors involving the midline. As the reported studies were published from 1999 up until now, we must take into account the evolution in imaging techniques. The introduction of MRI and PET/CT has significantly improved the nodal staging, facilitated the selection of subgroups and thereby reduced the likelihood of cRF. In addition, the use of chemotherapy differed greatly between studies. For example, in the study of Dan et al. 89% of patients received chemotherapy, compared to 28% in the study of Kennedy et al.<sup>72,75</sup> A significant amount of patients in the above mentioned studies was treated with older radiotherapy techniques, in which the contralateral neck can be treated, not-intentionally, to dose levels which might be enough to sterilize occult disease. As some older studies used 2D-3D RT techniques,<sup>61,68,70,77</sup> more recent studies made use of the newer intensity-modulated radiation therapy (IMRT) technique.<sup>33,71</sup> Some studies combined 3D and IMRT techniques.<sup>69,72-75</sup> However, as also noted by the group of Al-Mamgani, the incidence of cRF was not significantly increased by the use of conformal radiotherapy techniques.<sup>80</sup> The definition of well-lateralized tumor was not clear in all studies, although most studies defined it as the lateral one-third of the base of tongue/soft palate or at least 1 cm away from the midline. Finally, almost no studies stratified according to HPV status. As the incidence of HPV positive OPSCC has significantly increased over the last three decades, incidence of cRF and patient outcome of the older studies might not be translatable to the present.

According to the above-mentioned studies, cRF after UNI in OPSCC is rare, but still occurs in a significant part of patients treated with UNI, depending on the risk factors. The pioneer study of O'Sullivan demonstrated that extension of the primary tumor into midline structures was highly predictive of cRF. Later studies have added multiple node involvement as predictor for cRF. We need to keep in mind that even after bilateral ENI, cRF occurs in 2.8% of cases.<sup>81</sup> Nevertheless, proper case selection and adherence to guidelines for the use of a unilateral approach are essential. The American Society of Clinical Oncology advises to treat patients with T1-T2 and N0-N1 well-lateralized tonsillar cancer, without soft palate extension or base of tongue involvement, with UNI.<sup>82</sup> For patients with T1-2 lateralized N2a and N2b tonsillar cancer, guidelines are less clear-cut, as they state that UNI may be delivered, after careful weighing the relative benefits of unilateral treatment versus the potential risk for cRF. The ambiguity about the UNI of N2b disease is

reflected in slight differences in guidelines. For example, the American Radium Society did not reach consensus this year about the UNI of patients with N2b OPSCC, due to the lack of level 1 evidence supporting specific treatment decisions.<sup>83</sup> However, 2012 ACR Appropriateness Criteria recommend bilateral neck irradiation in case of  $\geq$ N2b.<sup>36</sup> Table 3 provides an overview of the existing evidence for the elective treatment of the neck, depending on subsite and tumor specifics. Since inclusion criteria were not uniform in all reviewed studies, prospective, preferably randomized, clinical trials addressing the suitability of UNI in HNSCC are needed.

#### 4 | THE VALUE OF THE SENTINEL LYMPH NODE BIOPSY

Over the last years, sentinel lymph node biopsy (SLNB) has emerged as an alternative or additional staging procedure for cervical lymph nodes.<sup>84</sup> The procedure is based on the concept that tumor cells spread from the primary site to a single node or group of nodes, before progressing to the remainder of the lymph nodes. The biology of HNSCC seems ideally suited for this technique, as we know that the dissemination of disease happens in a relatively orderly manner from one nodal basin to the next.<sup>7,9,44,85</sup> A radiotracer, possibly in conjunction with colored dye, injected into the primary tumor allows for identifying the sentinel nodes. Visualization of the sentinel nodes can be performed with the help of a lymphoscintigraphy, either or not with SPECT/CT, or with the intraoperative use of a hand-held gamma probe and/or portable gamma-camera with excision and histopathological evaluation of the sentinel nodes. The first experience with SLNB in HNSCC was published by Alex and Krag in 1996.<sup>86</sup> Since then, many centers followed with validation and observational studies. For assessment of the SLNB procedure, negative predictive value (NPV) is commonly used, representing the probability of a negative neck dissection after a negative SLNB. To date, the predominant clinical experience with SLNB has been with oral cavity tumors. Multiple studies have assessed the reliability of SLNB in cT1-2N0 OCSCC.<sup>87-95</sup> Govers et al. performed a meta-analysis on these studies and found a NPV ranging from 92% to 100%.<sup>84</sup> In 2014, the results of a Dutch multi-institutional trial involving four institutions and 62 patients found SLNB to have a sensitivity of 80% and a NPV of 88%.<sup>96</sup> The prospective EORTC Sentinel European Node Trial (SENT) recruited 415 patients with T1-2 OCSCC.<sup>97</sup> Positive SNs were found in 23%. A false-negative result occurred in 14% of patients, sensitivity of SLNB was 86%, and NPV was 95%. The latest and largest meta-analysis comprising 66 studies and 3566 patients indicated that

TABLE 3 Overview of recommendations, depending on subsite and tumor specifics

Subsite		Recommendation	Level of evidence (grade)				
Oral cavity		Definitive unilateral RT: patients unfit for surgery who would normally receive unilateral neck dissection <sup>83,155</sup>	Moderate				
Oropharynx	Isolated tonsillar cancer cT1-2	cN0 or single node, $\leq 3$ cm	ASTRO <sup>154</sup>	NCCN <sup>155</sup>	ASCO <sup>83</sup>	Moderate	
		Unilateral RT	Unilateral RT	Unilateral RT			
		Multiple ipsilateral nodes (cN2b) $\leq 6$ cm	Bilateral RT	N.R.	Uni/bilateral RT <sup>a</sup>		Low
		Tongue base extension	Bilateral RT	Bilateral RT	Uni/bilateral RT <sup>b</sup>		Low
	Soft palate extension	Uni/bilateral RT <sup>c</sup>	Bilateral RT	Uni/bilateral RT <sup>b</sup>	Low		
	Tonsillar cancer cT3-4	Bilateral RT <sup>83,154,155</sup>				Moderate	
	Tongue base cancer	ASTRO <sup>154</sup>	NCCN <sup>155</sup>	ASCO <sup>83</sup>			
	Lateralized	Bilateral RT	Bilateral RT	Unilateral RT	Low		
	Approaching midline	Bilateral RT	Bilateral RT	Bilateral RT	Moderate		
Other subsites OPC		Bilateral RT <sup>83,154,155</sup>	Moderate				
Hypopharynx		Bilateral RT <sup>155-157</sup>	Strong evidence for current guidelines, no reported trials for UNI				
Larynx	Supraglottic/subglottic carcinoma	Bilateral RT <sup>155,157</sup>					
	Glottic carcinoma	Bilateral RT (no ENI for cT1 <sup>d</sup> ) <sup>156,158-161</sup>					
Nasopharynx		Bilateral RT <sup>155,157</sup>					

Note: Level of evidence is scored according to the GRADE system. Some institutions report their results of T2 glottic tumors treated with the same approach<sup>161</sup>; however, this is not generally recommended. As early stage oral cavity carcinomas are mostly treated surgically, elective neck dissection is the preferred approach. However, if surgery is not feasible, unilateral RT can be performed if patients would qualify for a unilateral neck dissection according to existing surgery guidelines.<sup>83,155</sup> Regarding the treatment of tonsillar carcinoma and tongue base carcinoma, ASTRO, NCCN, and ASCO have inconsistent recommendations. Moderate evidence for unilateral RT in oropharyngeal carcinoma currently only exists for cT1-2 tonsillar carcinoma with single node  $\leq 3$  cm. Abbreviations: ASCO, American Society of Clinical Oncology; ASTRO, American Society for Radiation Oncology; NCCN, National Comprehensive Cancer Network; N.R., no recommendation.

<sup>a</sup>Unilateral RT may be delivered after careful weighing the benefits of unilateral RT versus the potential risk.

<sup>b</sup>Bilateral RT if within 1 cm of midline.

<sup>c</sup>Unilateral RT if  $<1$  cm soft palate extension.

<sup>d</sup>For T1 glottic carcinomas, observation of the neck is generally recommended.<sup>156,158-160</sup>

SLNB has an excellent diagnostic accuracy for predicting occult cervical LN metastases in clinical T1-T2N0 OCSCC, with a NPV of 94%.<sup>98</sup> A significant amount of studies includes both oral cavity and oropharyngeal cancers, stage T1-T2N0 with NPV ranging between 88% and 100%.<sup>99-109</sup> In these studies, OCSCCs and OPSCCs are considered as one group. However, they have different characteristics,

which can cause different results for SLNB. In the mentioned studies, OCSCC were significantly over-represented as compared to OPSCC. Furthermore, only a few subsites of OPSCC were investigated (mostly soft palate and base of tongue). Broglie et al. were the first to investigate the reliability of SLNB in 111 patients with exclusively T1-2 oropharyngeal cancers.<sup>110</sup> They found a NPV of 96%.

It is clear that the SLNB concept has been investigated frequently for oral and, to a lesser extent, for oropharyngeal cancer. However, less research has been done in the area of laryngeal and hypopharyngeal cancer. Tomifuji et al. reported the results of SLNB procedure on 20 patients with cT2-4N0 laryngeal and hypopharyngeal cancer and found an accuracy of 95%.<sup>111</sup> Interestingly, 40% of patients expressed a bilateral lymphatic spread pattern and the incidence of occult metastasis was much lower in glottic cancer (14%) compared to hypopharyngeal cancer (67%), which confirms empirical evidence. Lawson et al. performed SLNB on 29 patients with T1-3N0 supraglottic cancer<sup>112</sup> and reported a NPV between 91% and 100%. An important finding in this study is that the only additional positive lymph node that was not found with the SLNB technique was in the prelaryngeal region, an area where the activity at the injection site might hide the SLN (shine-through effect). Flach et al. reported sentinel lymph node identification in 92% of 13 included laryngeal cancer patients with a previously untreated neck.<sup>113</sup> Lopez et al. found a NPV of 78.6% in N0 laryngeal patients.<sup>114</sup> Some other studies, mainly investigating OC/OPSCC, included some patients with LC and HPC<sup>99,103,115–118</sup> and concluded that SLNB technique for patients with N0 appears to be safe. However, it is important to note that the number of LC and especially patients with HPC in these studies was very limited.

For early stage OCSCC, multiple studies proved that SLNB procedure counts as a reliable staging method and may serve as an alternative for elective neck dissection in experienced centres.<sup>119</sup> Yoshimoto and Hoft reported a significant higher false negative rate for T3 OCSCC compared to early stages.<sup>103,118</sup> Of note is that T3 tumors in these studies were classified according the 7th TNM edition, meaning that these tumors were larger than 4 cm. It might be more difficult for a larger primary tumor site to be completely surrounded by injected radiocolloid. Until further research is carried out, T3 OC tumors, particularly if larger than 4 cm, do not qualify for SLNB procedure. This is confirmed by the 2020 National Comprehensive Cancer Network (NCCN) guidelines that advise SLNB only for T1-T2 oral cavity tumors. Several studies found SLNB to be less reliable for floor-of-mouth tumors, presumably due to the close proximity of the injection site to the primary draining nodes with a consequent shine-through effect.<sup>88–90,109,120</sup> Although this finding was not confirmed by the EORTC SENT study, a Dutch multicenter retrospective study showed a significant different sensitivity for floor-of-mouth tumors ( $n = 131$ ) compared to tumors of other oral cavity sites ( $n = 357$ ): 63% vs. 86%. NPV was 90% and 95%, respectively.<sup>121</sup> NCCN guidelines therefore mention that caution must be exercised when replacing neck dissection by SLNB in floor-of-mouth tumors. Concerning

OPSCC, only one study performed SNLB on a substantial amount of patients.<sup>110</sup> The low number of patients with oropharyngeal cancers in the other studies did not allow pooling the results for OPSCC. In addition, not all oropharyngeal subsites were represented. Therefore, we may not simply assume that the high sensitivity of SLNB for OCSCC applies for all OPSCC. The same is true for laryngeal and hypopharyngeal cancers, which were significantly underrepresented in the few studies including LC and HPC. The above mentioned studies report rather wide ranges of NPV and sensitivity, which can presumably be explained by various causes. First, slightly different inclusion criteria are applied. For example, in the multicenter study of Flach et al.,<sup>96</sup> 36% of patients had a floor-of-mouth tumor, which may negatively influence accuracy, whereas these patients were excluded in several other studies. Second, a statistically significant difference in NPV between experienced and novice surgeons has been observed.<sup>122</sup> The EORTC SENT study reported a 14% false negative rate partially due to the learning curve effect.<sup>97</sup> Another limitation, possibly influencing the reported results, is that the quality of histopathological analysis of SLNB and neck dissection specimens is different to evaluate and may vary across institutions. A recent meta-analysis reports a significant difference in sensitivity of SLNB between studies where immunohistochemistry and step serial sectioning was performed, compared to older studies in which these techniques were not applied.<sup>161</sup> Furthermore, accuracy of SLNB is influenced by the choice of reference standard, which differed between studies. Some studies performed neck dissection irrespective of the SLNB result, while others reserved neck dissection for SLNB positive patients only, in combination with long-term observation of SLNB negative patients.<sup>84,96–98</sup> Follow-up of the untreated neck seems to be a better reference standard, since histopathological examination may miss minimal disease, leading to overestimation of sensitivity and NPV. Lastly, the incidence of occult lymph node metastases and follow-up time need to be taken into account, as they affect NPV and sensitivity, respectively. Determination of N0-disease differed between studies, as visualized in Table 1(A) of the meta-analysis of Govers et al.<sup>84</sup>

## 5 | SPECT/CT-GUIDED ELECTIVE NODAL IRRADIATION

Several studies have proven that SPECT/CT has the potential to detect more SLNs than dynamic planar lymphoscintigraphy alone.<sup>120,123–130</sup> As a result, the interest for SPECT/CT-guided elective radiation treatment has been increasing. Daisne et al. were the first to examine the feasibility of SPECT/CT lymphoscintigraphy for

selective prophylactic irradiation of the neck in patients with cN0 head and neck cancer.<sup>131</sup> The group of Antoni Van Leeuwenhoek hospital recently published the results of their prospective SUSPECT trial investigating feasibility, safety, and benefits of SPECT/CT-guided ENI of the node-negative contralateral neck.<sup>132</sup> Fifty patients with lateralized T1-3N0-2b tumors of the oropharynx, oral cavity, larynx, and hypopharynx underwent SPECT/CT after peritumoural 99mTc-nanocolloid injection. Patients without contralateral lymph drainage received UNI (82%). If drainage to only one contralateral lymph node was visible, ENI to the contralateral neck was limited to only the level containing the SLN (18%). After a median follow-up of 33 months, cRF was observed in only one patient (2%). The patient had a T2N2b tonsillar fossa carcinoma that was treated unilaterally and developed a contralateral lymph node metastasis in level II. A similar prospective, non-randomized phase I-II study was conducted by Longton et al.<sup>133</sup> Forty-four patients with tumors of oropharynx, oral cavity, larynx (except glottis cT1), or hypopharynx and cN0 stage received ENI of all node levels containing up to the four hottest SLNs. Four patients developed a nodal relapse, of which only 1 (2.3%) occurred outside the elective volume. It was a cT4a left soft palate tumor not crossing the midline that presented purely contralateral lymphatic drainage according to SPECT/CT, although the patient developed an ipsilateral recurrence in level Ib. These findings suggest that one can maybe avoid contralateral ENI in absence of contralateral lymphatic drainage, but not ipsilateral ENI in advanced stage tumors.

Although the results of the prospective studies regarding SPECT/CT-guided ENI are promising, we must be careful to draw firm conclusions regarding the current clinical practice. An important advantage of SLNB is its ability to identify “skip” metastases. Unpredictable lymphatic drainage patterns for lateralized tumors were reported in 9%–16% of cases.<sup>88,96,97,133,134</sup> For midline tumors, Mølstrøm et al. observed exclusive unilateral lymphatic drainage in 28.5% of patients, whereas the European SENT trial reported 40%.<sup>97,135</sup> However, limitations are the relatively small sample size and the heterogeneous distribution of tumoral subsites. In both studies, OPSCC and LC were much more prevalent, compared to the low number of patients with OCSCC and HPC. Furthermore, the role of concomitant chemotherapy was not evaluated. One of the most important limitations of the SLN technique is the risk of a false-negative result. This was well illustrated by the case of the patient, showing a lymphatic drainage exclusively contralateral to the tumor, that relapsed shortly after in the ipsilateral neck.<sup>133</sup> The authors hypothesized that the presence of a subclinical nodal metastasis obstructed the hilum of the node and therefore only contralateral drainage was

visualized. Therefore, it is mandatory to exclude gross lymph node involvement using conventional imaging, for example, CT, MRI, and/or ultrasound. Another possibility could be that in large tumors deep drainage would not be mapped. Nevertheless, it seems that the inclusion criteria for both studies might be too broadly defined and that the existing evidence on patient selection for SLNB was not sufficiently considered. The same applies for the contralateral relapse in the T2N2b tonsillar cancer patient in the study of De Veij Mestdagh et al.<sup>132</sup> Given the uncertainties about N2b stage for UNI, the inclusion of N2b patients may have been unfortunate, especially since most studies assessing reliability of SLN have been performed on patients with cN0. We can conclude that SLNB has become a well investigated nodal staging tool, but there remain some uncertainties that require further research before implementing SPECT/CT-guided ENI. Before conducting new radiotherapy trials, it seems appropriate to firstly validate the reliability of the SLN procedure on  $\geq$ T3, N+, and floor-of-mouth OC tumors and OPSCC, LC, and HPC. The higher resolution of PET/CT may solve the problem of “shine through phenomenon” for lymphoscintigraphy of floor-of-mouth OC tumors.<sup>136</sup>

## 6 | VOLUME DE-ESCALATION IN HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA

Over the past few decades, the incidence of human papillomavirus (HPV)-associated cancers of the oropharynx has increased, while the incidence of HPV negative tobacco-driven OPSCC has declined. Patients with HPV positive OPSCC tend to be more frequently male, younger, and have a better performance status and prognosis.<sup>137</sup> It is therefore desirable to minimize long-term toxicity in this population. Over the last years, the interest in dose and volume de-escalation in the HPV positive population has increased. Although the general consensus exists that treatment de-escalation for HPV positive OPSCC is feasible, the optimal approach has not yet been established. Concerning volume de-escalation, only few studies evaluating the safety of UNI made a distinction between patients with HPV positive and HPV negative, as most studies predate the HPV era. Furthermore, TNM8 staging for HPV positive tumors was not taken into account yet and current guidelines are based on studies using the TNM7-classification. Interestingly, patients HPV positive tend to present more often with multiple lymph nodes, so the question if UNI is suitable in the presence of multiple ipsilateral lymph nodes is especially relevant in this population.<sup>138</sup> Ye et al. reported



slightly higher cRF rates in patients with HPV positive treated with UNI (3.5% for HPV positive patients versus 2.5% for patients with HPV negative,  $p = 0.63$ ).<sup>139</sup> This was not confirmed by Liu et al.,<sup>73</sup> although HPV status was unknown for a significant part of the patient cohort. Huang et al. conducted a retrospective review of a cohort of T1-T2 tonsillar cancers treated with UNI and B-ENI between 1999 and 2014.<sup>140</sup> Only two patients developed a cRF, of which one patient was HPV positive and the other was HPV negative. In the OPTIMA trial, patients with HPV positive OPSCC stratified into low and high risk, received three cycles of induction chemotherapy and the radiation dose was determined based on response to chemotherapy.<sup>141</sup> Notably, the study also includes volume de-escalation, as the elective volume was limited to the first echelon of noninvolved nodes at the time of diagnosis. The authors conclude that a risk-stratified dose and volume de-escalated radiotherapy after induction chemotherapy is associated with favorable oncologic outcomes. All findings support the American Radium Society's advice that HPV status is not a contraindication for UNI.<sup>83</sup>

## 7 | EFFECTS ON TREATMENT-RELATED TOXICITY

The most important advantage of UNI for well-selected patients is the decrease in dose deliverance to the contralateral neck and important organs at risk, such as the salivary glands and the swallowing muscles. B-ENI (compared to UNI) has been identified as a strong predictor for grade  $\geq 2$  dysphagia and xerostomia at 6 months after treatment<sup>142–144</sup> and worse HRQOL scores at the EORTC QLQ-HN35 dry mouth and swallowing subscales.<sup>145</sup> A significant reduction of toxicity in patients treated with UNI, compared to B-ENI, was found in a prospective study by Jensen et al., with 20% versus 61% for grade  $\geq 2$  xerostomia and 10% versus 22% for grade  $\geq 2$  dysphagia.<sup>77</sup> Similar results were reported by Liu et al. (toxicity rate of 22% vs. 7%,  $p = 0.013$ ) with the caveat that these series had an imbalance in disease stages between the UNI and B-ENI group.<sup>73</sup> In addition, bilateral treatment in their series was delivered by nonconformal techniques. A lower acute and late toxicity profile using UNI was also reported by Al-Mamgani et al.,<sup>71</sup> as they compared toxicity results with a large series on IMRT for OPSCC.<sup>146</sup> Cramer et al. reported a smaller rate of hospitalization (17% vs. 61%,  $p < 0.01$ ) and less weight loss (6.3% vs. 8.4%) in patients treated with UNI.<sup>67</sup> Chronowski et al. reported a significantly lower acute dysphagia-related toxicity.<sup>69</sup> In the OPTIMA trial, acute grade 3+ mucositis, grade 3+ dermatitis, and the need for PEG-tube were significantly lower with de-escalated treatment.<sup>141</sup> Bilateral

neck irradiation was one of the most important predictors for PEG-tube dependency in 450 patients with HNSCC treated by chemoradiation.<sup>151</sup> It is therefore clear that a strictly UNI will generally lead to less toxicity and better quality of life. However, we need to keep in mind that the mentioned studies included patients that met the current conditions for UNI. These patients represent only part of patients with HNSCC. Therefore, we need to take into account a tumor site effect on the toxicity profiles for the group that was treated with B-ENI. For example, a base of tongue tumor in close proximity to the midline will lead to higher dose on swallowing structures compared to a lateralized tonsil tumor, regardless of the elective neck treatment.

With regard to the SPECT/CT guided ENI studies, evaluating toxicity benefits is somewhat more complex because not all patients were irradiated purely unilaterally. In the study of De Veij Mestdagh et al., compared to the matched B-ENI group, patients treated with SPECT/CT-guided ENI had significantly lower incidences of grade  $\geq 2$  dysphagia (54% vs. 82%;  $p < 0.001$ ), tube feeding (10% vs. 50%;  $p < 0.001$ ), and late grade  $\geq 2$  xerostomia (9% vs. 54%;  $p < 0.001$ ).<sup>132</sup> For dysphagia, hypothyroidism and laryngeal edema, significantly larger NTCP reductions were found in the group that received UNI. Inclusion criteria for both SPECT/CT-guided ENI studies are rather broad, as they include tumors originating from all subsites. Dysphagia is known to be mainly dependent on the mean dose to the pharyngeal constrictor muscles and the supraglottic larynx.<sup>147</sup> As these are midline structures, dysphagia might be reduced less in primary tumors crossing the midline. However, Longton et al.<sup>133</sup> observed a significant decrease of mean dose on several swallowing structures in SPECT/CT-guided ENI group, particularly in the case of unilateral lymphatic drainage. It is assumed that severe xerostomia could be avoided if at least 1 parotid gland were spared to a mean dose  $\leq 20$  Gy or if the mean dose to both parotid glands were  $\leq 25$  Gy.<sup>148</sup> In the study of Longton et al., more than 50% of the patients presented with bilateral lymphatic drainage. Therefore, the impact of a SPECT/CT-guided ENI on toxicity could be reduced, as an important part of OCSCC and OPSCC will drainage to contralateral level II, which is close to the parotid gland. Still, a significant reduction of the mean dose to the parotid glands was observed in HPC/LC tumors with a bilateral lymphatic drainage, probably due to the preferential drainage to level III.<sup>133</sup>

## 8 | FUTURE PERSPECTIVES

The EORTC Head and Neck Cancer Group recently presented a future trial, EORTC2047, which will be a phase

III randomized controlled trial to investigate SPECT/CT-guided elective contralateral neck treatment in lateralized OPSCC. Inclusion will be limited to patients with T1-T3 tonsillar or base of tongue cancer not involving the midline, with no contralateral nodes or involved ipsilateral nodes not larger than 6 cm on imaging. In the experimental arm, patients will receive UNI and SPECT/CT-guided contralateral ENI. The control arm will receive B-ENI according to international guidelines.<sup>13</sup> The INFIELD trial (NCT03067610) is a prospective phase II dose and volume de-escalation study for stage I-IV OPSCC and LC (with exclusion of stage I-II glottic cancer). The EVADER trial (NCT03822897) is a Canadian Cancer Trials Group phase II study to evaluate the efficacy of primary definitive (chemo)radiotherapy utilizing volume reduced ENI in patients with low-risk HPV positive OPSCC. The SAVER trial (NCT04609280) will also investigate volume de-escalation in the HPV positive population, however combined with dose de-escalation. The SUSPECT2 study aims to expand the inclusion criteria of the original SUSPECT study, with inclusion of stage T1-4N0-2b HNSCC not crossing the midline.<sup>132</sup> If no contralateral drainage is visualized, the patient will be treated with UNI. In case of contralateral lymph drainage, a contralateral SLNB will be performed. If pathologic evaluation finds no metastasis, the patient is treated with UNI. In Belgium, the SEMIRAHN trial was recently presented. This is a prospective randomized multicenter phase II study of dose and volume de-escalation. Patients with OC/OPSCC, LC, and HPC with ipsilateral lymph node metastases will be included. Patients with contralateral drainage according to <sup>99m</sup>Tc-nanocolloid drainage will be randomized between two different arms: whole level versus SLN only irradiation. Patients with the primary tumor not crossing the midline, expressing ipsilateral drainage only, will receive UNI. Patients with the primary tumor crossing the midline, expressing ipsilateral drainage only, will be excluded.

Other approaches with higher resolution lymphography using nonradioactive tracers currently under investigation include MRI and CT lymphography. These techniques use peritumoral injections of gadolinium- and iodine-based contrast agents, respectively, and may be used to guide unilateral or bilateral ENI in patients with HNSCC and even neck treatment of selected lymph node levels.<sup>149,150</sup>

Reducing the elective nodal volume in the radiotherapy of HNSCC thus holds a great promise to reduce both acute and long-term side effects for the patient. However, accurate selection criteria and close follow-up of the untreated neck are primordial not to compromise tumor control rates. Results of ongoing clinical trials will

hopefully deliver good criteria allowing a more restrictive approach regarding nodal dose-volumes.

## DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

## ORCID

Sandra Nuyts  <https://orcid.org/0000-0002-5540-4796>

Primoz Strojjan  <https://orcid.org/0000-0002-0445-112X>

William M. Mendenhall  <https://orcid.org/0000-0002-6592-2810>

Remco DeBree  <https://orcid.org/0000-0001-7128-5814>

## REFERENCES

1. Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study global burden of disease cancer collaboration. *JAMA Oncol.* 2017;3:524-548.
2. Petrelli F, Coinu A, Riboldi V, et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. *Oral Oncol.* 2014;50:1041-1048.
3. Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. *Lancet Oncol.* 2017;18(9):1221-1237.
4. Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol.* 2009;92(1):4-14.
5. Snow GB, van den Brekel MW, Leemans CR, Patel P. Surgical management of cervical lymph nodes in patients with oral and oropharyngeal cancer. *Recent Results Cancer Res.* 1994;134:43-55.
6. Lindberg RD, Barkley HT, Jesse RH, Fletcher GH. Evolution of the clinically negative neck in patients with squamous cell carcinoma of the faucial arch. *Am J Roentgenol Radium Ther Nucl Med.* 1971;111(1):60-65.
7. Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. *Cancer.* 1990;66(1):109-113.
8. Byers RM, Wolf PF, Ballantyne AJ. Rationale for elective modified neck dissection. *Head Neck Surg.* 1988;10(3):160-167.
9. Werner JA, Dünne AA, Myers JN. Functional anatomy of the lymphatic drainage system of the upper aerodigestive tract and its role in metastasis of squamous cell carcinoma. *Head Neck.* 2003;25:322-332.
10. MacComb W, Fletcher GH. Planned combination of surgery and radiation in treatment of advanced primary head and neck cancers. *Am J Roentgenol Radium Ther Nucl Med.* 1957;77(3):397-414.
11. Barkley H, Fletcher GH, Jesse RH, Lindberg RD. Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx. *Am J Surg.* 1972;124(4):462-467.

12. Grégoire V, Levendag P, Ang K, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. *Radiother Oncol.* 2003;69(3):227-236.
13. Biau J, Lapeyre M, Troussier I, et al. Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 update. *Radiother Oncol.* 2019;134:1-9.
14. van den Bosch S, Vogel WV, Raaijmakers CP, et al. Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: radiotherapy target volume transformation and dose de-escalation. *Radiother Oncol.* 2018;128:472-478.
15. Sun R, Tang X, Yang Y, Zhang C. 18FDG-PET/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis. *Oral Oncol.* 2015;51(4):314-320.
16. Norling R, Buron BMD, Therikildsen MH, Henriksen BM, Von Buchwald C, Nielsen MB. Staging of cervical lymph nodes in oral squamous cell carcinoma: adding ultrasound in clinically lymph node negative patients may improve diagnostic work-up. *PLoS One.* 2014;9(3):e90360.
17. Heusch P, Sproll C, Buchbender C, et al. Diagnostic accuracy of ultrasound, 18F-FDG-PET/CT, and fused 18F-FDG-PET-MR images with DWI for the detection of cervical lymph node metastases of HNSCC. *Clin Oral Investig.* 2014;18(3):969-978.
18. Lowe VJ, Duan F, Subramaniam RM, et al. Multicentre trial of [18F]fluorodeoxyglucose positron emission tomography/computed tomography staging of head and neck cancer and negative predictive value and surgical impact in the n0 neck: results from acrin 6685. *J Clin Oncol.* 2019;37(20):1704-1712.
19. Pitman KT. Rationale for elective neck dissection. *Am J Otolaryngol.* 2000;21(1):31-37.
20. Wei W, Ferlito A, Rinaldo A, et al. Management of the N0 neck—reference or preference. *Oral Oncol.* 2006;42(2):115-122.
21. Weiss M, Harrison L, Isaacs R. Use of decision analysis in planning a management strategy for the stage N0 neck. *Arch Otolaryngol Head Neck Surg.* 1994;120(7):699-702.
22. Mukherji SK, Armao D, Joshi VM. Cervical nodal metastases in squamous cell carcinoma of the head and neck: what to expect. *Head Neck.* 2001;23(11):995-1005.
23. Ferlito A, Silver C, Rinaldo A. Elective management of the neck in oral cavity squamous carcinoma: current concepts supported by prospective studies. *Br J Oral Maxillofac Surg.* 2009;47(1):5-9.
24. González-García R, Naval-Gías L, Sastre-Pérez J, et al. Contralateral lymph neck node metastasis of primary squamous cell carcinoma of the tongue: a retrospective analytic study of 203 patients. *Int J Oral Maxillofac Surg.* 2007;36(6):507-513.
25. Ganly I, Goldstein D, Carlson DL, et al. Long-term regional control and survival in patients with “low-risk,” early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumour thickness. *Cancer.* 2013;119(6):1168-1176.
26. Koo BS, Lim YC, Lee JS, Choi EC. Management of contralateral n0 neck in oral cavity squamous cell carcinoma. *Head Neck.* 2006;28(10):896-901.
27. Kowalski LP, Bagietto R, Lara JRL, Santos RL, Tagawa EK, Santos IRB. Factors influencing contralateral lymph node metastasis from oral carcinoma. *Head Neck.* 1999;21(2):104-110.
28. Kurita H, Koike T, Narikawa J, et al. Clinical predictors for contralateral neck lymph node metastasis from unilateral squamous cell carcinoma in the oral cavity. *Oral Oncol.* 2004;40(9):898-903.
29. Wenzel S, Sagowski C, Kehrl W, Metternich FU. The prognostic impact of metastatic pattern of lymph nodes in patients with oral and oropharyngeal squamous cell carcinomas. *Eur Arch Oto-Rhino-Laryngol.* 2004;261(5):270-275.
30. Sanguineti G, Califano J, Stafford E, et al. Defining the risk of involvement for each neck nodal level in patients with early T-stage node-positive oropharyngeal carcinoma. *Int J Radiat Oncol Biol Phys.* 2009;74(5):1356-1364.
31. Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable head and neck tumours based on RTOG 85-03 and 88-24: targets for postoperative radiochemotherapy. *Head Neck.* 1998;20(7):588-594.
32. Vergeer MR, Doornaert PAH, Jonkman A, et al. Ipsilateral irradiation for oral and oropharyngeal carcinoma treated with primary surgery and postoperative radiotherapy. *Int J Radiat Oncol Biol Phys.* 2010;78(3):682-688.
33. Lynch J, Lal P, Schick U, et al. Multiple cervical lymph node involvement and extra-capsular extension predict for contralateral nodal recurrence after ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. *Oral Oncol.* 2014;50(9):901-906.
34. Candela FC, Kothari K, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. *Head Neck.* 1990;12(3):197-203.
35. Al-Mamgani A, Verheij M, van den Brekel MWM. Elective unilateral nodal irradiation in head and neck squamous cell carcinoma: a paradigm shift. *Eur J Cancer.* 2017;82:1-5.
36. Yeung AR, Garg MK, Lawson J, et al. ACR appropriateness criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil. *Head Neck.* 2012;34(5):613-616.
37. Perez CA, Patel MM, Chao KSC, et al. Carcinoma of the tonsillar fossa: prognostic factors and long-term therapy outcome. *Int J Radiat Oncol Biol Phys.* 1998;42(5):1077-1084.
38. Dziegielewski PT, O'Connell DA, Szudek J, et al. Neck metastases in oropharyngeal cancer: Necessity and extent of bilateral treatment. *Head Neck.* 2012;35(10):1461-1467.
39. Olzowy B, Tsalemchuk Y, Schotten KJ, Reichel O, Harréus U. Frequency of bilateral cervical metastases in oropharyngeal squamous cell carcinoma: a retrospective analysis of 352 cases after bilateral neck dissection. *Head Neck.* 2011;33(2):239-243.
40. McMullen C, Garneau J, Weimar E, et al. Occult contralateral nodal disease in oropharyngeal squamous cell carcinoma patients undergoing primary TORS with bilateral neck dissection. *Oral Oncol.* 2019;93:96-100.
41. Kjems J, Gothelf A, Håkansson K, Spech L, Kristensen C, Friborg J. Elective nodal irradiation and patterns of failure in head and neck cancer after primary radiation therapy. *Int J Radiat Oncol Biol Phys.* 2016;94(4):775-782.
42. Lim YC, Lee SY, Lim JY, et al. Management of contralateral N0 neck in tonsillar squamous cell carcinoma. *Laryngoscope.* 2005;115(9):1672-1165.
43. De Oliveira Santos AB, Cernea CR, Inoue M, Ferraz AR. Selective neck dissection for node-positive necks in patients with head and neck squamous cell carcinoma: a word of caution. *Arch Otolaryngol Head Neck Surg.* 2006;132(1):79-81.

44. Woolgar JA. The topography of cervical lymph node metastases revisited: the histological findings in 526 sides of neck dissection from 439 previously untreated patients. *Int J Oral Maxillofac Surg*. 2007;36(3):219-225.
45. Chow TL, Chow TK, Chan TTF, Yu NF, Fung SC, Lam SH. Contralateral neck recurrence of squamous cell carcinoma of oral cavity and oropharynx. *J Oral Maxillofac Surg*. 2004;62(10):1225-1228.
46. Koo BS, Lim YC, Lee JS, Kim YH, Kim SH, Choi EC. Management of contralateral N0 neck in pyriform sinus carcinoma. *Laryngoscope*. 2006;116(7):1268-1272.
47. Buckley JG, MacLennan K. Cervical node metastases in laryngeal and hypopharyngeal cancer: a prospective analysis of prevalence and distribution. *Head Neck*. 2000;22(4):380-385.
48. Rucci L, Gallo O, Fini-Storchi O. Contralateral metastasis in patients with cancer of the larynx and the hypopharynx. Analysis and critical review of our caseload. *Acta Otorhinolaryngol Ital*. 1990;10(1):11-18.
49. Biller HF, Davis WH, Ogura JH. Delayed contralateral cervical metastases with laryngeal and laryngopharyngeal cancers. *Laryngoscope*. 1971;81(9):1499-1502.
50. Johnson JT, Bacon GW, Myers EN, Wagner RL. Medial vs lateral wall pyriform sinus carcinoma: implications for management of regional lymphatics. *Head Neck*. 1994;16(5):401-405.
51. Joo YH, Sun D-I, Cho KJ, Cho JH, Kim MS. The impact of paratracheal lymph node metastasis in squamous cell carcinoma of the hypopharynx. *Eur Arch Otorhinolaryngol*. 2010;267(6):945-950.
52. Marks J, Devineni V, Harvey J, Sessions D. The risk of contralateral lymphatic metastases for cancers of the larynx and pharynx. *Am J Otolaryngol*. 1992;13(1):34-39.
53. Aluffi P, Pisani P, Policarpo M, Pia F. Contralateral cervical lymph node metastases in pyriform sinus carcinoma. *Otolaryngol Head Neck Surg*. 2006;134(4):650-653.
54. Khan MK, Koyfman SA, Hunter GK, Reddy CA, Saxton JP. Definitive radiotherapy for early (T1-T2) glottic squamous cell carcinoma: A 20 year cleveland clinic experience. *Radiat Oncol*. 2012;7(1):193-200.
55. Stokes W, Abbott D, Phan A, Raben D, Lanning R, Karam S. Patterns of care for patients with early-stage glottic cancer undergoing definitive radiation therapy: a national cancer database analysis. *Int J Radiat Oncol Biol Phys*. 2017;98(5):1014-1021.
56. Öztürkcan S, Katılmış H, Özdemir I, Tuna B, Güvenç IA, Dündar R. Occult contralateral nodal metastases in supraglottic laryngeal cancer crossing the midline. *Eur Arch Otorhinolaryngol*. 2009;266(1):117-120.
57. Weber P, Johnson J, Myers E. The impact of bilateral neck dissection on pattern of recurrence and survival in supraglottic carcinoma. *Arch Otolaryngol Head Neck Surg*. 1994;120(7):703-706.
58. Böttcher A, Olze H, Thieme N, et al. A novel classification scheme for advanced laryngeal cancer midline involvement: implications for the contralateral neck. *J Cancer Res Clin Oncol*. 2017;143(8):1605-1612.
59. Sanabria A, Shah JP, Medina JE, et al. Incidence of occult lymph node metastasis in primary larynx squamous cell carcinoma, by subsite, T classification and neck level: a systematic review. *Cancer*. 2020;12(4):1059.
60. Liu B, Guan C, Ji W, Pan Z. Impact of extracapsular lymph node spread in the ipsilateral neck on contralateral neck metastasis and prognosis of laryngeal cancer. *Zhonghua Zhong Liu Za Zhi*. 2006;28(11):871-875.
61. O'Sullivan B, Warde P, Grice B, et al. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. *Int J Radiat Oncol Biol Phys*. 2001;51(2):332-343.
62. Hu KS, Mourad WF, Gamez M, et al. Low rates of contralateral neck failure in unilaterally treated oropharyngeal squamous cell carcinoma with prospectively defined criteria of lateralization. *Head Neck*. 2017;39(8):1647-1654.
63. Maskell D, Buckley H, Sission K, Roques T, Geropantas K. Ipsilateral neck radiotherapy in N2b well-lateralized tonsil cancer—approach with caution. *Head Neck*. 2019;41(9):2937-2946.
64. Rusthoven KE, Raben D, Schneider C, Witt R, Sammons S, Raben A. Freedom from local and regional failure of contralateral neck with Ipsilateral neck radiotherapy for node-positive tonsil cancer: results of a prospective management approach. *Int J Radiat Oncol Biol Phys*. 2009;74(5):1365-1370.
65. Rackley TP, Namelo WC, Palaniappan N, Cole N, Owens DMJ, Evans M. Unilateral radiotherapy for surgically resected lateralized squamous cell carcinoma of the tonsil. *Head Neck*. 2017;39(1):17-23.
66. Chin RI, Rao YJ, Hwang MY, et al. Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil. *Cancer*. 2017;123(23):4594-4607.
67. Cramer CK, Paltal M, Patel P, Brizel DM. Ipsilateral tonsil chemoradiation: improved toxicity compared to bilateral radiation and effective rates of local-regional control. *Int J Radiat Oncol*. 2014;88(2):477.
68. Kagei K, Shirato H, Nishioka T, et al. Ipsilateral irradiation for carcinomas of tonsillar region and soft palate based on computed tomographic simulation. *Radiother Oncol*. 2000;54(2):117-121.
69. Chronowski GM, Garden AS, Morrison WH, et al. Unilateral radiotherapy for the treatment of tonsil cancer. *Int J Radiat Oncol Biol Phys*. 2012;83(1):204-209.
70. Jackson SM, Hay JH, Flores AD, et al. Cancer of the tonsil: the results of ipsilateral radiation treatment. *Radiother Oncol*. 1999;51(2):123-128.
71. Al-Mamgani A, Van Rooij P, Fransen D, Levendag P. Unilateral neck irradiation for well-lateralized oropharyngeal cancer. *Radiother Oncol*. 2013;106(1):69-73.
72. Kennedy WR, Herman MP, Deraniyagala RL, et al. Ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. *Eur Arch Otorhinolaryngol*. 2016;273(8):2151-2156.
73. Liu C, Dutu G, Peters LJ, Rischin D, Corry J. Tonsillar cancer: the Peter MacCallum experience with unilateral and bilateral irradiation. *Head Neck*. 2014;36(3):317-322.
74. Koo TR, Wu HG. Long-term results of ipsilateral radiotherapy for tonsil cancer. *Radiat Oncol J*. 2013;31(2):66-71.
75. Dan TD, Raben D, Schneider CJ, et al. Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: updated results of an institutional clinical management approach. *Oral Oncol*. 2015;51(6):616-621.

76. Cerezo L, Martín M, López M, Marín A, Gómez A. Ipsilateral irradiation for well lateralized carcinomas of the oral cavity and oropharynx: results on tumour control and xerostomia. *Radiat Oncol.* 2009;4(1):33.
77. Jensen K, Overgaard M, Grau C. Morbidity after ipsilateral radiotherapy for oropharyngeal cancer. *Radiother Oncol.* 2007; 85(1):90-97.
78. Kim Y, Cho KH, Moon SH, et al. Comparison of the clinical outcomes of patients with squamous cell carcinoma of the tonsil receiving postoperative ipsilateral versus bilateral neck radiotherapy: a propensity score matching analysis (KROG 11-07). *Cancer Res Treat.* 2017;49(4):1097-1105.
79. Sher DJ, Pham N-L, Shah JL, et al. Prospective phase II study of radiotherapy dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer. *Int J Radiat Oncol.* 2020;109(4):932-940.
80. Al-Mamgani A, van Werkhoven E, Navran A, et al. Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: a literature-based critical review. *Cancer Treat Rev.* 2017;59:102-108.
81. de Veij Mestdagh PD, van Werkhoven E, Navran A, et al. Incidence of contralateral regional failure in the electively irradiated contralateral neck of patients with head and neck squamous cell carcinoma. *Clin Transl Radiat Oncol.* 2019;17:7-13.
82. Koyfman SA, Ismaila N, Crook D, et al. Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: ASCO clinical practice guideline. *J Clin Oncol.* 2019; 37:1753-1774.
83. Tsai CJ, Galloway TJ, Margalit DN, et al. Ipsilateral radiation for squamous cell carcinoma of the tonsil: American radium society appropriate use criteria executive summary. *Head Neck.* 2021;43(1):392-406.
84. Govers TM, Hannink G, Merckx MAW, Takes RP, Rovers MM. Sentinel node biopsy for squamous cell carcinoma of the oral cavity and oropharynx: a diagnostic meta-analysis. *Oral Oncol.* 2013;49:726-732.
85. Woolgar JA. Histological distribution of cervical lymph node metastases from intraoral/oropharyngeal squamous cell carcinomas. *Br J Oral Maxillofac Surg.* 1999;37(3):175-180.
86. Alex JC, Krag DN. The gamma-probe-guided resection of radiolabeled primary lymph nodes. *Surg Oncol Clin N Am.* 1996;5(1):33-41.
87. Alvarez Amézaga J, Barbier Herrero L, Pijoan Zubizarreta JJ, et al. Sentinel node in head and neck cancer diagnostic efficacy of sentinel node biopsy in oral squamous cell carcinoma. Cohort study and meta-analysis. *Med Oral Patol Oral Cir Bucal.* 2007;12(3):235-243.
88. Civantos FJ, Moffat FL, Goodwin WJ. Lymphatic mapping and sentinel lymphadenectomy for 106 head and neck lesions: contrasts between oral cavity and cutaneous malignancy. *Laryngoscope.* 2006;116:1-15.
89. Civantos FJ, Zitsch RP, Schuller DE, et al. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. *J Clin Oncol.* 2010;28(8):1395-1400.
90. Jeong HS, Baek CH, Son YI, et al. Sentinel lymph node radiolocalization with <sup>99m</sup>Tc filtered tin colloid in clinically node-negative squamous cell carcinomas of the oral cavity. *J Korean Med Sci.* 2006;21(5):865-870.
91. Kontio R, Leivo I, Leppänen E, Atula T. Sentinel lymph node biopsy in oral cavity squamous cell carcinoma without clinically evident metastasis. *Head Neck.* 2004;26(1):16-21.
92. Melkane AE, Mamelle G, Wycisk G, et al. Sentinel node biopsy in early oral squamous cell carcinomas: a 10-year experience. *Laryngoscope.* 2012;122(8):1782-1178.
93. Pezier T, Nixon IJ, Gurney B, et al. Sentinel lymph node biopsy for T1/T2 oral cavity squamous cell carcinoma: a prospective case series. *Ann Surg Oncol.* 2012;19(11):3528-3533.
94. Rigual N, Douglas W, Lamonica D, et al. Sentinel lymph node biopsy: a rational approach for staging T2N0 oral cancer. *Laryngoscope.* 2005;115(12):2217-2220.
95. Terada A, Hasegawa Y, Yatabe Y, et al. Follow-up after intraoperative sentinel node biopsy of N0 neck oral cancer patients. *Eur Arch Oto-Rhino-Laryngol.* 2011;268(3):429-435.
96. Flach GB, Bloemena E, Klop WMC, et al. Sentinel lymph node biopsy in clinically N0 T1-T2 staged oral cancer: the Dutch multicentre trial. *Oral Oncol.* 2014;50(10):1020-1024.
97. Schilling C, Stoeckli SJ, Haerle SK, et al. Sentinel European node trial (SENT): 3-year results of sentinel node biopsy in oral cancer. *Eur J Cancer.* 2015;51(18):2777-2784.
98. Liu M, Wang SJ, Yang X, Peng H. Diagnostic efficacy of sentinel lymph node biopsy in early oral squamous cell carcinoma: a meta-analysis of 66 studies. *PLoS One.* 2017;12(1):e0170322.
99. Barzan L, Sulfaro S, Alberti F, et al. Gamma probe accuracy in detecting the sentinel lymph node in clinically N0 squamous cell carcinoma of the head and neck. *Ann Otol Rhinol Laryngol.* 2002;111(9):794-798.
100. Burns P, Foster A, Walshe P, O'Dwyer T. Sentinel lymph node biopsy in node-negative squamous cell carcinoma of the oral cavity and oropharynx. *J Laryngol Otol.* 2009;123 (4):439-443.
101. Vorburger MS, Broglie MA, Soltermann A, et al. Validity of frozen section in sentinel lymph node biopsy for the staging in oral and oropharyngeal squamous cell carcinoma. *J Surg Oncol.* 2012;106(7):816-819.
102. Hart RD, Nasser JG, Trites JR, Taylor SM, Bullock M, Barnes D. Sentinel lymph node biopsy in NO squamous cell carcinoma of the oral cavity and oropharynx. *Arch Otolaryngol Head Neck Surg.* 2005;131(1):34-38.
103. Höft S, Maune S, Muhle C, et al. Sentinel lymph-node biopsy in head and neck cancer. *Br J Cancer.* 2004;91(1):124-128.
104. Minamikawa T, Umeda M, Komori T. Reliability of sentinel lymph node biopsy with squamous cell carcinoma of the oral cavity. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2005;99(5):532-538.
105. Pitman KT, Johnson JT, Brown ML, Myers EN. Sentinel lymph node biopsy in head and neck squamous cell carcinoma. *Laryngoscope.* 2002;112(12):2101-2113.
106. Stoeckli SJ, Alkureishi LWT, Ross GL. Sentinel node biopsy for early oral and oropharyngeal squamous cell carcinoma. *Eur Arch Oto-Rhino-Laryngol.* 2009;266:787-793.
107. Taylor RJ, Wahl RL, Sharma PK, et al. Sentinel node localization in oral cavity and oropharynx squamous cell cancer. *Arch Otolaryngol Head Neck Surg.* 2001;127(8):970-974.
108. Burcia V, Costes V, Faillie JL, et al. Neck restaging with sentinel node biopsy in T1-T2N0 oral and oropharyngeal cancer: Why and how. *Otolaryngol Head Neck Surg.* 2010;142(4):592-597.e1.

109. Alkureishi LWT, Ross GL, Shoaib T, et al. Sentinel node biopsy in head and neck squamous cell cancer: 5-year follow-up of a european multicentre trial. *Ann Surg Oncol*. 2010;17(9):2459-2464.
110. Broglie MA, Haerle SK, Huber GF, Haile SR, Stoeckli SJ. Occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinomas: impact on survival. *Head Neck*. 2013;35(5):660-666.
111. Tomifuji M, Shiotani A, Fujii H, et al. Sentinel node concept in clinically N0 laryngeal and hypopharyngeal cancer. *Ann Surg Oncol*. 2008;15(9):2568-2575.
112. Lawson G, Matar N, Nollevaux MC, et al. Reliability of sentinel node technique in the treatment of N0 supraglottic laryngeal cancer. *Laryngoscope*. 2010;120(11):2213-2217.
113. Flach GB, Bloemena E, van Schie A, et al. Sentinel node identification in laryngeal cancer: feasible in primary cancer with previously untreated neck. *Oral Oncol*. 2013;46(2):165-168.
114. López Mollá C, Morales Suárez-Varela M, Carrasco Llatas M, Sopena Monforte R, López Martínez R, Dalmau GJ. Sentinel lymph node in tumours of the larynx: technique and results. *Acta Otorrinolaringol Esp*. 2006;57(7):307-312.
115. Werner JA, Dünne AA, Ramaswamy A, et al. The sentinel node concept in head and neck cancer: solution for the controversies in the N0 neck? *Head Neck*. 2004;26(7):603-611.
116. Werner JA, Dünne AA, Ramaswamy A, et al. Sentinel node detection in N0 cancer of the pharynx and larynx. *Br J Cancer*. 2002;87(7):711-715.
117. Muhle C, Brenner W, Südmeyer M, et al. CT-guided lymphoscintigraphy in patients with squamous cell carcinoma of the head and neck: a feasibility study. *Eur J Nucl Med Mol Imaging*. 2004;31(7):940-944.
118. Yoshimoto S, Hasegawa Y, Matsuzuka T, et al. Sentinel node biopsy for oral and laryngopharyngeal squamous cell carcinoma: a retrospective study of 177 patients in Japan. *Auris Nasus Larynx*. 2012;39(1):65-70.
119. De Bree R, de Keizer B, Civantos FJ, et al. What is the role of sentinel lymph node biopsy in the management of oral cancer in 2020? *Eur Arch Oto-Rhino-Laryngol*. 2020. <https://doi.org/10.1007/s00405-020-06538-y>.
120. Ross GL, Soutar DS, MacDonald DG, et al. Sentinel node biopsy in head and neck cancer: preliminary results of a multicentre trial. *Ann Surg Oncol*. 2004;11(7):690-696.
121. Den Toom IJ, Boeve K, Lobeek D, et al. Elective neck dissection or sentinel lymph node biopsy in early stage oral cavity cancer patients: the dutch experience. *Cancers (Basel)*. 2020;12(7):1783.
122. Valsecchi ME, Silbermins D, De Rosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. *J Clin Oncol*. 2011;29(11):1479-1487.
123. Shoaib T, Soutar DS, MacDonald DG, et al. The accuracy of head and neck, carcinoma sentinel lymph node biopsy in the clinically N0 neck. *Cancer*. 2001;91(11):2077-2283.
124. Koch W, Choti M, Civelek A, Eisele D, Saunders J. Gamma probe-directed biopsy of the sentinel node in oral squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg*. 1998;124(4):455-459.
125. Colnot DR, Nieuwenhuis EJC, Van den Brekel MWM, et al. Head and neck squamous cell carcinoma: US-guided fine-needle aspiration of sentinel lymph nodes for improved staging—initial experience. *Radiology*. 2001;218(1):289-293.
126. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. *Head Neck*. 2002;24(4):345-349.
127. Khafif A, Schneebaum S, Fliss DM, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid single photon emission CT (SPECT)/CT system in oral cavity squamous cell carcinoma. *Head Neck*. 2006;28(10):874-879.
128. Thomsen JB, Sørensen JA, Grupe P, Krogdahl A. Sentinel lymph node biopsy in oral cancer: validation of technique and clinical implications of added oblique planar lymphoscintigraphy and/or tomography. *Acta Radiol*. 2005;46(6):569-575.
129. Haerle SK, Hany TF, Strobel K, Sidler D, Stoeckli SJ. Is there an additional value of spect/ct over planar lymphoscintigraphy for sentinel node mapping in oral/oropharyngeal squamous cell carcinoma? *Ann Surg Oncol*. 2009;16(11):3118-3124.
130. den Toom IJ, van Schie A, van Weert S, et al. The added value of SPECT-CT for the identification of sentinel lymph nodes in early stage oral cancer. *Eur J Nucl Med Mol Imaging*. 2017;44(6):998-1004.
131. Daisne JF, Installé J, Bihin B, et al. SPECT/CT lymphoscintigraphy of sentinel node(s) for superselective prophylactic irradiation of the neck in cN0 head and neck cancer patients: a prospective phase I feasibility study. *Radiat Oncol*. 2014;9:121.
132. de Veij Mestdagh PD, Walraven I, Vogel WV, et al. SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: a potentially practice-changing approach. *Radiother Oncol*. 2020;147:56-63.
133. Longton E, Lawson G, Bihin B, et al. Individualized prophylactic neck irradiation in patients with cN0 head and neck Cancer based on sentinel lymph node(s) identification: definitive results of a prospective phase 1-2 study. *Int J Radiat Oncol Biol Phys*. 2020;107(4):652-661.
134. Moya-Plana A, Eupérin A, Guerlain J, et al. Sentinel node biopsy in early oral squamous cell carcinomas: long-term follow-up and nodal failure analysis. *Oral Oncol*. 2018;82:187-197.
135. Mølstrøm J, Grønne M, Green A, Bakholdt V, Sørensen JA. Topographical distribution of sentinel nodes and metastases from T1-T2 oral squamous cell carcinomas. *Eur J Cancer*. 2019;107:86-92.
136. Mahieu R, Krijger GC, Ververs FFT, de Roos R, de Bree R, de Keizer B. [68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy: a novel technique for sentinel lymph node imaging. *Eur J Nucl Med Mol Imaging*. 2020;48:963-965.
137. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med*. 2010;363(1):24-35.
138. O'Sullivan B, Huang S, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on oropharyngeal cancer network. *Lancet Oncol*. 2016;17(4):440-451.
139. Ye A, Bradley K, Kader H, Wu J, Hay JH. Patterns of relapse in squamous cell carcinoma of the tonsil-unilateral vs. bilateral radiation in the HPV-era. *Cureus*. 2015;7(9):e322.

140. Huang SH, Waldron J, Bratman SV, et al. Re-evaluation of ipsilateral radiation for T1-T2N0-N2b tonsil carcinoma at the Princess Margaret Hospital in the human papillomavirus era, 25 years later. *Int J Radiat Oncol Biol Phys.* 2017;98(1):159-169.
141. Seiwert TY, Foster CC, Blair EA, et al. Optima: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. *Ann Oncol.* 2019;30(2):297-302.
142. Langendijk JA, Doornaert P, Rietveld DHF, Verdonck-de Leeuw IM, René Leemans C, Slotman BJ. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. *Radiother Oncol.* 2009;90(2):189-195.
143. Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Unilateral versus bilateral irradiation in squamous cell head and neck cancer in relation to patient-rated xerostomia and sticky saliva. *Radiother Oncol.* 2007;85(1):83-89.
144. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. *Int J Radiat Oncol Biol Phys.* 2001;50(3):695-704.
145. Al-Mamgani A, Van Rooij P, Tans L, Verduijn GM, Sewnaik A, De Jong RJB. A prospective evaluation of patient-reported quality-of-life after (chemo)radiation for oropharyngeal cancer: Which patients are at risk of significant quality-of-life deterioration? *Radiother Oncol.* 2013;106(3):359-363.
146. Setton J, Caria N, Romanyshyn J, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Centre experience. *Int J Radiat Oncol Biol Phys.* 2012;82(1):291-298.
147. Dirix P, Abbeel S, Vanstraelen B, Hermans R, Nuyts S. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures. *Int J Radiat Oncol Biol Phys.* 2009;75(2):385-392.
148. Deasy J, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. *Int J Radiat Oncol Biol Phys.* 2010;76(3):S58-S63.
149. De Bree R, Dankbaar JW, De Keizer B. New developments in sentinel lymph node biopsy procedure in localized oral cancer. *JAMA Otolaryngol Head Neck Surg.* 2019;145(8):741-742.
150. Mahieu R, de Maar JS, Nieuwenhuis ER, et al. New developments in imaging for sentinel lymph node biopsy in early-stage oral cavity squamous cell carcinoma. *Cancers (Basel).* 2020;12(10):3055.
151. Willemsen ACH, Kok A, van Kuijk SMJ, et al. Prediction model for tube feeding dependency during chemoradiotherapy for at least four weeks in head and neck cancer patients: a tool for prophylactic gastrostomy decision making. *Clin Nutr.* 2020;39(8):2600-2608.
152. Sher DJ, Adelstein DJ, Bajaj GK, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: an ASTRO evidence based clinical practice guideline. *Pract Rad Oncol.* 2017;7:246-253.
153. National Comprehensive Cancer Network. Head and Neck Cancers (Version 1.2021).
154. Machiels JP, Leemans CR, Golusinski W, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2020;31:1462-1475.
155. ASTRO 2018 Update on radiation treatment for head/neck cancer.
156. Zumsteg ZS, Riaz N, Jaffery S, et al. Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma. *Oral Oncol.* 2015;51:716-723.
157. Rock K, Huang SH, Tiong A, et al. Partial laryngeal IMRT for T2N0 glottic cancer: impact of image guidance and radiation therapy intensification. *Int J Radiat Oncol Biol Phys.* 2018;102:941-949.
158. Bossi P, Chan AT, Licitra L, et al. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2020;32:P452-P465.
159. Lee A, Ng WT, Pan JJ, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. *Radiother Oncol.* 2018;126:25-36.
160. Lin L, Lu Y, Wang XJ, et al. Delineation of neck clinical target volume specific to nasopharyngeal carcinoma based on lymph node distribution and the international consensus guidelines. *Int J Radiat Oncol Biol Phys.* 2018;100:891-902.
161. Magariños M, Ajuria M, Mendía X, et al. Diagnostic yield of sentinel lymph node biopsy in oral squamous cell carcinoma T1/T2-N0: systematic review and meta-analysis. *Int J Oral Maxillofac Surg.* 2021. <https://doi.org/10.1016/j.ijom.2021.01.020>.

**How to cite this article:** Nuyts S, Bollen H, Eisbruch A, et al. Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck. *Head & Neck.* 2021;43:2807–2821. <https://doi.org/10.1002/hed.26713>